Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis

Iqbal, Javeed; Shen, Yulei; Liu, Yanyan; Fu, Kai; Jaffe, Elaine S.; Liu, Cuiling; Liu, Zhongfeng; Lachel, Cynthia M.; Deffenbacher, Karen; Greiner, Timothy C.; Vose, Julie M.; Bhagavathi, Sharathkumar; Staudt, Louis M.; Rimsza, Lisa M.; Rosenwald, Andreas; Ott, German; Delabie, Jan; Campo, Elı́as; Braziel, Rita M.; Cook, James R.; Tubbs, Raymond R.; Gascoyne, Randy D.; Armitage, Jamés O.; Weisenburger, Dennis D.; McKeithan, Timothy W.; Chan, Wing C.

doi:10.1182/blood-2011-07-370122

Cited by 89 publications

(68 citation statements)

References 46 publications

(73 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The miRNA profiles of B-cell lymphomas were used for comparative analysis and have been previously described. 25 The NPM-ALK(1) ALCL cell lines (SUP-M2/TS, Karpas 299, L82, JB6, and SUDHL-1) and ALK(-) ALCL cell line (MAC-1) were cultured in RPMI-1640 medium containing 10% fetal calf serum (Lonza, Rockland, ME), 2 mM L-glutamine, and 1% streptomycin. Normal T-cell CD3…”

Section: Patient Specimens Cell Lines and Normal Cellsmentioning

confidence: 99%

“…1 and B-cell subsets 25 were obtained from fresh tonsils as described previously 26 by using magnetic MACS microbeads according to the manufacturer's instructions (Miltenyi Biotec, Auburn, CA), and pooled RNA and miRNA from at least 6 to 9 healthy individuals was profiled in 3 different experimental settings. The stromal cells were isolated from minced human tonsils digested with 2 mg/mL collagenase type IV (Worthington Biochemical, Freehold, NJ) and 0.1 mg/mL DNase I (Sigma-Aldrich, St. Louis, MO) and processed as described previously.…”

Section: Patient Specimens Cell Lines and Normal Cellsmentioning

confidence: 99%

See 1 more Smart Citation

microRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma

Liu

Iqbal

Teruya‐Feldstein

et al. 2013

Blood

Self Cite

View full text Add to dashboard Cite

• Anaplastic large-cell lymphoma has a unique miRNA signature.• The miR-17;92 is an important downstream effector of ALK oncogenic pathway.Anaplastic large-cell lymphomas (ALCLs) encompass at least 2 systemic diseases distinguished by the presence or absence of anaplastic lymphoma kinase (ALK) expression. We performed genome-wide microRNA (miRNA) profiling on 33 ALK-positive (ALK[1]) ALCLs, 25 ALK-negative (ALK[2]) ALCLs, 9 angioimmunoblastic T-cell lymphomas, 11 peripheral T-cell lymphomas not otherwise specified (PTCLNOS), and normal T cells, and demonstrated that ALCLs express many of the miRNAs that are highly expressed in normal T cells with the prominent exception of miR-146a. Unsupervised hierarchical clustering demonstrated distinct clustering of ALCL, PTCL-NOS, and the AITL subtype of PTCL. Cases of ALK(1) ALCL and ALK(-) ALCL were interspersed in unsupervised analysis, suggesting a close relationship at the molecular level. We identified an miRNA signature of 7 miRNAs (5 upregulated: miR-512-3p, miR-886-5p, miR-886-3p, miR-708, miR-135b; 2 downregulated: miR-146a, miR-155) significantly associated with ALK(1) ALCL cases. In addition, we derived an 11-miRNA signature (4 upregulated: miR-210, miR-197, miR-191, miR-512-3p; 7 downregulated: miR-451, miR-146a, miR-22, miR-455-3p, miR-455-5p, miR-143, miR-494) that differentiates ALK(-) ALCL from other PTCLs. Our in vitro studies identified a set of 32 miRNAs associated with ALK expression. Of these, the miR-17∼92 cluster and its paralogues were also highly expressed in ALK(1) ALCL and may represent important downstream effectors of the ALK oncogenic pathway.

show abstract

Section: Patient Specimens Cell Lines and Normal Cellsmentioning

confidence: 99%

Section: Patient Specimens Cell Lines and Normal Cellsmentioning

confidence: 99%

microRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma

Liu

Iqbal

Teruya‐Feldstein

et al. 2013

Blood

Self Cite

View full text Add to dashboard Cite

show abstract

“…[84][85][86][87] Overexpression of members of the miR-17∼92 cluster, for example, has been associated with high MYC levels in aggressive MCL, 86 and inhibition of chemotherapyinduced apoptosis in MCL cell lines, 88 while downregulation of miR-29 has been proposed as a potential prognostic marker for this malignancy. 84 …”

Section: Mantle Cell Lymphoma (Mcl)mentioning

confidence: 99%

MicroRNAs as B-cell lymphoma biomarkers

Manterola¹,

Fernández-Mercado²,

Larrea³

et al. 2015

BLCTT

View full text Add to dashboard Cite

B-cell lymphomas represent a group of more than 35 recognized mature B-cell neoplasms differentiated largely on the basis of immunohistochemical staining patterns that are often challenging to accurately diagnose. Despite having been only formally recognized just over 10 years ago, microRNAs (miRNAs) have become one of the trendiest topics in biology. Dysregulation of miRNAs is a ubiquitous feature of cancer in general, including B-cell lymphomas. Many of the miRNAs aberrantly expressed in B-cell lymphomas also play a crucial regulatory role in normal hematopoietic function. MiRNAs show great potential as novel biomarkers of cancer, as they can differentiate cancers according to diagnosis and developmental stage, even discriminating between cancers that are poorly separated histologically. Furthermore, they can be robustly measured from routinely prepared formalin-fixed paraffin-embedded biopsy material and biological fluids such as blood. Here, we consider the identity, function, and biomarker potential of miRNAs in B-cell lymphomas and, most importantly, the hurdles that remain to be overcome if they are really to become part of future clinical practice.

show abstract

“…Finally, a refined version of the MIPI-b that integrates other biomarkers may further improve the reliability of a risk-adapted therapeutic approach (69,81,82).…”

Section: Looking For a Tailored Therapy In MCLmentioning

confidence: 99%

New Paradigms in Mantle Cell Lymphoma: Is It Time to Risk-Stratify Treatment Based on the Proliferative Signature?

Dreyling

Ferrero

Vogt

et al. 2014

Clinical Cancer Research

View full text Add to dashboard Cite

The elucidation of crucial biologic pathways of cell survival and proliferation has led to the development of highly effective drugs, some of which have markedly improved mantle cell lymphoma (MCL) therapeutic opportunities in the past 10 years. Moreover, an undeniable clinical heterogeneity in treatment response and disease behavior has become apparent in this neoplasm. Thus, the need for biologic markers stratifying patients with MCL in risk classes deserving different treatment approaches has recently been fervently expressed. Among several newly discovered biomarkers, the dismal predictive value of a high proliferative signature has been broadly recognized in large studies of patients with MCL. Different techniques have been used to assess tumor cell proliferation, including mitotic index, immunostaining with Ki-67 antibody, and gene expression profiling. Ki-67 proliferative index, in particular, has been extensively investigated, and its negative impact on relapse incidence and overall survival has been validated in large prospective clinical trials. However, one important pitfall limiting its widespread use in clinical practice is the reported interobserver variability, due to the previous lack of a standardized approach for quantification among different laboratories. In the present review, we describe some of the major techniques to assess cell proliferation in MCL, focusing in particular on the Ki-67 index and its need for a standardized approach to be used in multicenter clinical trials. The value of MCL biologic prognostic scores (as MIPI-b) is discussed, along with our proposal on how to integrate these scores in the planning of future trials investigating a tailored therapeutic approach for patients with MCL.

show abstract

Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis

Cited by 89 publications

References 46 publications

microRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma

microRNA expression profiling identifies molecular signatures associated with anaplastic large cell lymphoma

MicroRNAs as B-cell lymphoma biomarkers

New Paradigms in Mantle Cell Lymphoma: Is It Time to Risk-Stratify Treatment Based on the Proliferative Signature?

Contact Info

Product

Resources

About